Novosti

Povratak

FEBS Journal – “Special Issue on Cancer Therapeutics”

FEBS Journal – “Special Issue on Cancer Therapeutics”

Objavljeno 21.12.2021.

Izašlo je posebno izdanje časopisa “FEBS Journal” Special Issue on Cancer Therapeutics, posvećeno problematici istraživanja raka. Ovo izdanje donosi pregled najnovijih spoznaja o razvoju moguće terapije kroz niz preglednih radova.

Više možete pronaći na linku “Special Issue on Cancer Therapeutics”

Popis objavljenih članaka:

  1. Watson CJ (2021) The ever-expanding landscape of cancer therapeutic approaches. FEBS J. 288, 6082– 6086.
  2. Skourti E & Letai A (2021) In conversation with Tony Letai. FEBS J 288, 6087– 6093.
  3. van der Zanden SY, Qiao X & Neefjes J (2020) New insights into the activities and toxicities of the old anticancer drug doxorubicin. FEBS J 288, 6094– 6110.
  4. Ashe H, Krakowiak P, Hasterok S, Sleppy R, Roller DG & Gioeli D (2021) Role of the runt-related transcription factor (RUNX) family in prostate cancer. FEBS J 288, 6111– 6125.
  5. Chatwin HV, Cruz Cruz J & Green AL (2021) Pediatric high-grade glioma: moving toward subtype-specific multimodal therapy. FEBS J 288, 6126– 6140.
  6. Dupont CA, Riegel K, Pompaiah M, Juhl H & Rajalingam K (2021) Druggable genome and precision medicine in cancer: current challenges. FEBS J 288, 6141– 6157.
  7. Robinson RA, McMurran C, McCully ML & Cole DK (2021) Engineering soluble T-cell receptors for therapy. FEBS J 288, 6158– 6172.
  8. Yan S & Wan G (2021) Tumor-associated macrophages in immunotherapy. FEBS J 288, 6173– 6185.
  9. Wu L, Lian W & Zhao L (2021) Calcium signaling in cancer progression and therapy. FEBS J 288, 6186– 6204.
  10. Läubli H, Kawanishi K, Vazhappilly CG, Matar R, Merheb M & Siddiqui SS (2021) Tools to study and target the Siglec–sialic acid axis in cancer. FEBS J 288, 6205– 6224.
  11. Wang JZ, Lin TE, Wang K, Zhu H, Conway RM, Madigan MC, Murray M, Cherepanoff S, Zhou F & Shu W (2021) Development of new therapeutic options for the treatment of uveal melanoma. FEBS J 288, 6225– 6248.
  12. Naro C, Bielli P & Sette C (2021) Oncogenic dysregulation of pre-mRNA processing by protein kinases: challenges and therapeutic opportunities. FEBS J 288, 6249– 6271.
  13. Kemler I, Karamched B, Neuhauser C & Dingli D (2021) Quantitative imaging and dynamics of tumor therapy with viruses. FEBS J 288, 6272– 6284.
  14. Damen MPF, van Rheenen J & Scheele CLGJ (2020) Targeting dormant tumor cells to prevent cancer recurrence. FEBS J 288, 6285– 6302.